Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Candel Therapeutics, Inc.
Study ID
NCT03131037
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CAN-2409 + valacyclovir — BIOLOGICAL
    CAN-2409 will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each injection.

Study Details

This is a phase I dose escalation study of CAN-2409 plus prodrug in patients with non-small cell lung cancer (NSCLC). The primary clinical objective of the study is to evaluate the safety of CAN-2409 plus prodrug when combined with standard surgery for NSCLC. The primary scientific objective is to determine the immunologic changes induced by CAN-2409 plus prodrug.

Key Dates

Start date
May 4, 2017
Status verified
Jul 2025
Primary completion
Dec 1, 2021
Completion
Sep 20, 2023

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study Arm
    CAN-2409 + valacyclovir

Primary Outcome Measure

Incidence of treatment emergent adverse events [ Time Frame: 6 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Pennsylvania· Philadelphia, PA

Related Studies